High-risk febrile neutropenia and its management in children with solid tumors and lymphoma

Basit Öğe Kaydı
dc.contributor.authorKose, Dogan
dc.contributor.authorEmiroglu, Melike
dc.contributor.authorKoksal, Yavuz
dc.date.accessioned2020-03-26T19:06:04Z
dc.date.available2020-03-26T19:06:04Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground/aim: The clinical characteristics and treatment results of febrile neutropenia attacks that occurred in patients with lymphoma and solid tumors were analyzed. Materials and methods: A total of 50 patients with 94 high-risk attacks were evaluated for malignant diseases in this study. Results: The fever etiology was determined as clinical (50%), microbiological (5.31%), clinical-microbiological (5.31%), or unknown (39.3%). A few of the attacks (21.3%) were observed in lymphoma cases and 77.7% were observed in patients with solid tumors. Patients who were in remission had 59.6% of the attacks, and 39.4% occurred in patients not in remission. Among the groups tested, 73% (the imipenem/amikacin group) and 47.9% (the piperacillin-tazobactam/amikacin group) of patients were in remission. Glycopeptide addition rates in these groups were 22.2% and 40.8% and antifungal addition rates were 8.8% and 18.3%, respectively. Conclusion: Clinical progress was more problematic in patients who were not in remission during the attacks. This was due to the fact that some patients had other factors that placed them in the high-risk group, as well as increased C reactive protein and procalcitonin values on the first day. Therefore, it may not be accurate to associate the success achieved in the different treatment regimens with antibiotics alone.en_US
dc.identifier.doi10.3906/sag-1402-94en_US
dc.identifier.endpage662en_US
dc.identifier.issn1300-0144en_US
dc.identifier.issn1303-6165en_US
dc.identifier.issue3en_US
dc.identifier.pmid26281335en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage655en_US
dc.identifier.urihttps://dx.doi.org/10.3906/sag-1402-94
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32206
dc.identifier.volume45en_US
dc.identifier.wosWOS:000356357800028en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEYen_US
dc.relation.ispartofTURKISH JOURNAL OF MEDICAL SCIENCESen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChildhooden_US
dc.subjectfebrileen_US
dc.subjecthigh risken_US
dc.subjectneutropeniaen_US
dc.titleHigh-risk febrile neutropenia and its management in children with solid tumors and lymphomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu